Hironori Shiozaki

Hironori Shiozaki

Auto-generated profile, based on publicly available information

Hironori Shiozaki

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2016 in Oncology
Verified
Journal Article
Open access
PDF file
Nikolaos CharalampakisNikolaos Charalampakis
Nikolaos Charalampakis
GNGraciela Nogueras
Graciela Nogueras
EEElena Elimova
Elena Elimova
RWRoopma Wadhwa
Roopma Wadhwa
HSHironori Shiozaki
Hironori Shiozaki
Jaffer AjaniJaffer Ajani
Jaffer Ajani
Background: Patients with localized gastric adenocarcinoma (LGAC), who get pre-operative therapy, have heterogeneous/unpredictable outcomes. Predictive clinical variables/biomarkers are not established. Methods: We analyzed 107 LGAC patients who had chemoradiation and surgery. LGACs were grouped for (1) presence/absence of signet ring cell histology (SRC) and (2) histologic grade: G2 or G3. %SRC was assessed (0, 1-10, 11-49, and 50-100%) and correlated with pathologic complete response (pathCR) or <pathCR in the resected specimens. Results: Most patients were men (60%), had stage cIII LGAC (50%), and received chemotherapy before chemoradiation (93%). Most had G3 tumors (78%) and SRC (58%). Presence of SRC was associated with a lower rate of pathCR (11 vs. 36%, p = 0.004), and the association remained significant even with a low percentage of SRC (1-10%; p = 0.014). The higher the fraction of SRC, the lower was the probability of pathCR (p = 0.03). G3 and SRC led to a shorter overall survival (OS) (p = 0.046 and p = 0.038, respectively). yp stage independently prognosticated OS and recurrence-free survival (p < 0.001). Conclusion: Our novel findings suggest that LGACs with SRC are relatively chemoradiation resistant compared to LGACs without SRC. A higher fraction of SRC is associated with higher resistance. Upon validation/biomarker(s) evaluation, reporting of the fraction of SRC may be warranted.

1 January 2021 in Pancreatology
Verified
Journal Article
Closed access
KFKenei Furukawa
Kenei Furukawa
TGTakeshi Gocho
Takeshi Gocho
TSTaro Sakamoto
Taro Sakamoto
MTMasashi Tsunematsu
Masashi Tsunematsu
KHKoichiro Haruki
Koichiro Haruki
TIToru Ikegami
Toru Ikegami

27 March 2023 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
HSHironori Shiozaki
Hironori Shiozaki
KFKenei Furukawa
Kenei Furukawa
KHKoichiro Haruki
Koichiro Haruki
MMMichinori Matsumoto
Michinori Matsumoto
TUTadashi Uwagawa
Tadashi Uwagawa
TIToru Ikegami
Toru Ikegami
Background/Aim: Sorafenib was previously the only targeted therapy for hepatocellular carcinoma (HCC). However, pharmaceutical therapy for HCC has undergone remarkable advances in recent years. Herein, we report cases of unresectable advanced HCC responding to pharmaceutical therapy resulting in improved prognosis through surgical intervention. Patients and Methods: Five patients with intermediate and advanced stage HCC treated with lenvatinib followed by hepatectomy between October 2019 and September 2022 were retrospectively reviewed. Patient characteristics, tumor factors, and treatment factors were compared. Results: The median patient age was 66 (60-79) years, and all patients (100%) were male. The median follow-up period was 10.4 months. All five patients received lenvatinib treatment for more than 2 months before surgery. Three patients achieved partial responses and 2 patients had stable disease with modified RESIST in response to lenvatinib. Three patients had a partial pathological response (50% or more tumor necrosis). Four patients underwent R0 resection and 3 cases had no recurrence. Conclusion: Lenvatinib might be useful for intermediate and advanced HCC and long-term survival may be obtained by combining lenvatinib therapy with surgery.

8 April 2021 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
HSHironori Shiozaki
Hironori Shiozaki
YSYoshihiro Shirai
Yoshihiro Shirai
MSMachi Suka
Machi Suka
RHRyoga Hamura
Ryoga Hamura
THTakashi Horiuchi
Takashi Horiuchi
TIToru Ikegami
Toru Ikegami

1 June 2021 in Molecular and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HSHironori Shiozaki
Hironori Shiozaki
YSYoshihiro Shirai
Yoshihiro Shirai
THTakashi Horiuchi
Takashi Horiuchi
JYJungo Yasuda
Jungo Yasuda
KFKenei Furukawa
Kenei Furukawa
TIToru Ikegami
Toru Ikegami
Pancreatic neuroendocrine tumor (PNET) cases are increasing; however, the treatment indication and procedure remain unestablished. The present study evaluated the indication, feasibility and safety of laparoscopic distal pancreatectomy (LDP) with our technique for PNET. A total of 13 patients with insulinoma and nonfunctional PNET <2 cm in diameter who underwent LDP and 13 patients with any size of PNET who underwent open distal pancreatectomy (ODP) between October 2009 and June 2019 were retrospectively reviewed and compared. The median age of patients was 45 (33-61) years, and 14 (54%) patients were male. The median follow-up periods were 70 months for the LDP group and 46 months for the ODP group. The tumor diameter of the patients who underwent LDP for PNET was 18 +/- 9 mm compared with 37 +/- 25 mm for those who underwent ODP. The operation time, estimated blood loss, and complication were 290.2 +/- 115 vs. 337 +/- 131 min (P=0.338), 122 +/- 172 vs. 649 +/- 693 ml (P=0.019) and 31 vs. 54% (P=0.234), respectively. Pancreatic fistula developed in 8% of patients who underwent LDP compared with 31% who underwent ODP (P=0.131). Notably, the postoperative hospitalization period was significantly shorter in the LDP group (11 +/- 7 vs. 21 +/- 13 days; P=0.022). Tumor grade of 2017 World Health Organization classification (G1/G2/G3/NEC/unknown) was 9/2/0/0/2 for the LDP group compared with 5/5/0/3/0 for the ODP group. Furthermore, lymph node metastasis was detected in only 1 patient who underwent ODP, for whom the maximum tumor diameter was 70 mm and was classified as G2. In addition, 2 patients in the ODP group developed postoperative lung and liver metastases. LDP for PNETs of <2 cm in selected patients can be safely performed; however, the extent of lymph node dissection needs to be clarified.

1 December 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
TGTakeshi Gocho
Takeshi Gocho
KFKenei Furukawa
Kenei Furukawa
HSHironori Shiozaki
Hironori Shiozaki
JYJungo Yasuda
Jungo Yasuda
YSYoshihiro Shirai
Yoshihiro Shirai
TIToru Ikegami
Toru Ikegami
We recently enjoyed the article entitled published from Kyoto group (1) with much interest. They evaluated muscle mass index (MSI) and intramuscular adipose tissue content (IMAC), representing muscular mass and quality respectively, and fond that high muscularity donor with higher SMI and lower IMAC for age-adjusted values was the independent positive factor for survival.